Quételet (body mass) index and effects of dapagliflozin in chronic kidney disease.

Glenn M ChertowPriya VartNiels JongsAnna Maria LangkildeJohn Joseph Valentine McMurrayRicardo Correa-RotterPeter RossingC David SjöströmBergur V StefanssonRobert D TotoDavid C WheelerHiddo J Lambers Heerspink

Published in: Diabetes, obesity & metabolism (2022)

Among participants with CKD and albuminuria, with or without type 2 diabetes, kidney and cardiovascular benefits of dapagliflozin were evident and consistent across the BMI spectrum.

Keyphrases

type diabetes
chronic kidney disease
body mass index
glycemic control
cardiovascular disease
insulin resistance
physical activity
skeletal muscle
adipose tissue